MedPage today story.
Welcome to the latest version of Roundup, highlighting some of the best health care reports every week.
Missing my mother killing my mother
Instead, my mother’s routine action in Texas became a tragic example of medical misfortune, according to a report. in Texas monthly.
Kimberly Ray was getting the injection in the lower lumbar area of an old injury. But the injection stopped working, so its provider recommended obtaining root removal. Ray did not wake up from the procedure. Her family ordered an autopsy, which she found “died as a result of complications after the injection of pain.”
Then the family rented a lawyer, and his investigation found the red flag after the red flag associated with the integrity of wellness, the clinic in which Ray sought, and the medical staff associated with it.
For one of them, Crna who turned the anesthesia and conducted the procedure a white coat and realized and the family did not realize that he was not a doctor. A medical expert reviewed the issue of Ray and said that there is a “clear possibility” that her heart had stopped because the RNA, which gave her anesthesia that managed it in a way that caused “muscle paralysis that would prevent the recipient from breathing.”
The investigation found that the other ribbian rina in the room during the procedure, which was assigned to monitor Ray and failed to note that it did not suffer from a pulse and was not breathing, had its doubtful history.
Not to mention the practices of crazy bills. In a different clinic, the Rai Insurance invoices were 2000 dollars per injection. But integrity described wellness as $ 139,000 for the same service.
Since this tragic state in 2021, wellness has been renamed to the Cedarwood Surgical Center.
Avoid Ophon Titan Main Payment
Although there were a strong bill of dollars against it, the opium maker had to pay a small part of the people who were affected by its products, according to ProPublica.
In 2013, one of the amounts of violations filed a lawsuit against Endo Health Solutions to alert the government to the company’s dark practices. The lawsuit was accused of marketing the company “he was intentionally designed to manipulate doctors who described them.”
For example, in the previous years of the company, sales representatives have been stimulated to sell as much Percocet as possible with those who achieve the largest BMW sales. The sales team had joyful tactics to show “unique” features of the leading opium, Opana A, although these allegations contradict what the Food and Drug Administration said about the drug. Endo also continued to provide opiates for doctors who other black ball companies have been reckless.
A decade ago, the Ministry of Justice had a profitable issue with a wealth of evidence against Indo – but it was late in taking action. At that time, Endo dealt with the structure of her business and rearranged her debts to avoid accountability.
While Endo owed up to $ 7 billion, in the end, she only had to get $ 200 million. Only 40 million dollars have been divided between the victims of opioids, or about $ 1,000 each (to return to it, the victims of Purdue Pharma are scheduled to get between 3500 and 48,000 dollars each). Meanwhile, executive officials divided 95 million dollars of rewards, and lawyers exceeded $ 350 million.
Experience experience interrogated
Fifteen years after a historical experience of the BRILINTA anti -bachelors article, the data integration issues remain, according to an article in Bmj.
Ticagrelor is the only P2Y12 inhibitor that is still under the patent and achieves a great profit, despite the relatively small market share. But the central experience that supports its use has been interrogated for years. The clinical experiment included Plato 18,624 patients in 43 countries and found that Texjooror led to better results than its competitor, Clubidoukal, the oldest drug (Plavix).
However, only the sub -group analysis of the participants in the United States found that it was actually worse and had 27 % higher risk of death than the causes of blood vessels, myocardial infarction or stroke – the initial end point. Astrazneyca explained this far away, noting that “an unusually high aspirin dose is almost exclusively seen in the United States”, which did not convince the food and drug administration, which initially denied the Texture.
In most of the 43 countries, the sites were monitored by the same sponsor. However, “in the four countries that were monitored by non-sponsors-Georgia, Israel, Russia and the United States-Texagalur was worse.”
The trial was examined by the US Department of Justice in 2013, but the investigation was dropped after a year. The researchers reviewed the experience of the experiment and continued to raise the alarm about the integration of data and other experiments in repeating the results.